Journal
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
Volume 57, Issue 3, Pages 312-316Publisher
WALTER DE GRUYTER GMBH
DOI: 10.1515/cclm-2018-0610
Keywords
circulating tumor cells; liquid biopsy; minimal residual disease
Categories
Funding
- EU/IMI consortium CANCER-ID, an Innovative Medicines Initiative Joint Undertaking [115749]
- European Union's Seventh Framework Programme (FP7 Health/2007-2013)
Ask authors/readers for more resources
Liquid biopsy was introduced as a new diagnostic concept in 2010 for the analysis of circulating tumor cells (CTCs) and has been now extended to material (in particular DNA) released by tumor cells in the peripheral blood of cancer patients. Over the past decade, various methods have been developed to detect CTCs and ctDNA in the peripheral blood of cancer patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
